Want to see TWST full AI Analyst Report?
TWST Stock Chart & Stats
$90.27
-$2.17(-2.35%)
At close: 4:00 PM EDT
$90.27
-$2.17(-2.35%)
Day’s Range― - ―
52-Week Range$23.30 - $105.47
Previous CloseN/A
Volume1.05M
Average Volume (3M)1.79M
Market Cap
$5.70B
Enterprise Value$6.35K
Total Cash (Recent Filing)$166.84M
Total Debt (Recent Filing)$93.59M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Nov 13, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.22
Shares Outstanding62,271,313
10 Day Avg. Volume1,142,308
30 Day Avg. Volume1,792,237
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.56
Price to Sales (P/S)4.47
P/FCF Ratio-22.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$106.13Price Target Upside17.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.1
Revenue Forecast (FY)$446.39M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthFourteen consecutive quarters of growth and a 23% YoY Q3 print indicate durable commercial momentum across products and end markets. Sustained top-line expansion supports scale economics, broader customer adoption, and gives management runway to invest in R&D and go‑to‑market initiatives without relying solely on one-off deals.
Improving Gross Margins And Manufacturing ScaleLarge, multi-year manufacturing efficiency gains (material cost, waste, turnaround and capacity) have driven higher gross margins and create a sustainable cost advantage. These improvements support margin expansion toward the stated long-term >60% goal and enable profitable scaling as revenue grows.
Relatively Solid Balance Sheet And Moderate LeverageModerate debt and sizable equity provide financial flexibility for an unprofitable growth company. Lower leverage reduces near-term refinancing risk, supports continued capital spending on capacity and product launches, and gives management optionality to fund the path to adjusted EBITDA breakeven without immediate distress.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means the business continues to require external funding until cash generation inflects. This constrains reinvestment, increases dilution/refinancing risk, and limits flexibility to pursue capital-intensive opportunities or absorb adverse demand shocks during the multi-quarter path to profitability.
Ongoing Net Losses And Profitability RiskMaterial negative margins and sustained operating losses reduce internal capital generation and signal that operating leverage is not yet realized. Achieving promised adjusted EBITDA breakeven depends on execution and OpEx cuts; continued losses risk prolonged dilution and impair returns until consistent profitable quarters are delivered.
Order Conversion Timing And Demand Concentration RisksReliance on large, lumpy AI-driven orders and noted short order cycles introduce revenue recognition volatility and forecasting difficulty. Conversion timing and customer concentration can cause uneven quarter-to-quarter cash flow and complicate capacity planning, increasing execution risk as the company scales in competitive markets.
Twist Bioscience News
TWST FAQ
What was Twist Bioscience’s price range in the past 12 months?
Twist Bioscience lowest stock price was $23.30 and its highest was $105.47 in the past 12 months.
What is Twist Bioscience’s market cap?
Twist Bioscience’s market cap is $5.70B.
When is Twist Bioscience’s upcoming earnings report date?
Twist Bioscience’s upcoming earnings report date is Nov 13, 2026 which is in 100 days.
How were Twist Bioscience’s earnings last quarter?
Twist Bioscience released its earnings results on Aug 03, 2026. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.506 by -$0.054.
Is Twist Bioscience overvalued?
According to Wall Street analysts Twist Bioscience’s price is currently Undervalued.
Does Twist Bioscience pay dividends?
Twist Bioscience does not currently pay dividends.
What is Twist Bioscience’s EPS estimate?
Twist Bioscience’s EPS estimate is -0.39.
How many shares outstanding does Twist Bioscience have?
Twist Bioscience has 62,271,313 shares outstanding.
What happened to Twist Bioscience’s price movement after its last earnings report?
Twist Bioscience reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.506. Following the earnings report the stock price went up 10.388%.
Which hedge fund is a major shareholder of Twist Bioscience?
Currently, no hedge funds are holding shares in TWST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Twist Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$106.13 (17.56% Upside)
$106.13 (17.56% Upside)
Blogger Sentiment
Neutral
TWST Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
13.53%
Trailing 12-Months
Company Description
Twist Bioscience
Twist Bioscience Corporation (TWST) is a synthetic biology and life-sciences company that designs and manufactures synthetic DNA at scale. It serves customers across biotechnology, pharmaceutical research and development, academic and government labs, and applied markets, leveraging a silicon-based DNA synthesis platform to produce products such as custom DNA (including genes and fragments), oligonucleotide pools, NGS target enrichment tools, and antibody discovery/engineering reagents and services (including antibody libraries).
TWST Company Deck
TWST Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and commercial narrative: record revenue ($118.4M, +23% YoY), strong DSPS and therapeutics growth (+39% and +49% YoY respectively), improved gross margin (52.8%, +120 bps sequential), operational efficiency gains, and raised full-year guidance. Management reiterated confidence in triple-digit AI-enabled order growth for FY2026 and FY2027 and guided to adjusted EBITDA breakeven in Q4. Near-term risks include a Q3 adjusted EBITDA loss (~$11.3M), elevated OpEx, modest cash decline, some underperforming segments, and timing/visibility risks around order-to-revenue conversion and competitive dynamics. Overall, positive momentum and structural improvements outweigh the near-term profitability and timing challenges.View all TWST earnings summariesTWST Stock 12 Month Forecast
Average Price Target
$106.13
▲(17.56% Upside)
Technical Analysis
Ownership Overview
2.84% Insiders
27.24% Mutual Funds
4.89% Other Institutional Investors
38.98% Public Companies and
Individual Investors